InSilico Medicine (HKG:3696) said it will join Value Partners Shenzhen, Pudong Construction, and Hanchen Lanxi to establish a 610 million yuan fund to invest in growth-stage companies in biomedicine, life sciences, and artificial intelligence.
Insilico Pudong Development and Value Partners Shenzhen will serve as the fund's executive partners, the company said.
The fund will have a 10-year period, comprising a five-year investment period and a five-year exit period.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments